Contrarius Group Holdings Ltd Purchases New Shares in Tempus AI, Inc. $TEM

Contrarius Group Holdings Ltd purchased a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 135,026 shares of the company’s stock, valued at approximately $7,973,000.

A number of other hedge funds also recently bought and sold shares of TEM. JPL Wealth Management LLC bought a new position in shares of Tempus AI in the 3rd quarter valued at about $26,000. Los Angeles Capital Management LLC bought a new position in shares of Tempus AI in the 4th quarter valued at about $27,000. Harvest Fund Management Co. Ltd bought a new position in shares of Tempus AI in the 3rd quarter valued at about $38,000. Danske Bank A S bought a new position in shares of Tempus AI in the 3rd quarter valued at about $48,000. Finally, Sunbelt Securities Inc. bought a new position in shares of Tempus AI in the 3rd quarter valued at about $52,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Performance

Tempus AI stock opened at $46.43 on Monday. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. Tempus AI, Inc. has a 1-year low of $41.73 and a 1-year high of $104.32. The firm has a market capitalization of $8.34 billion, a P/E ratio of -26.99 and a beta of 3.64. The company’s 50-day moving average is $48.89 and its 200 day moving average is $57.42.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same period in the prior year, the company posted ($0.24) EPS. The firm’s revenue for the quarter was up 36.1% on a year-over-year basis. Research analysts forecast that Tempus AI, Inc. will post -1.35 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. BTIG Research reiterated a “buy” rating and issued a $80.00 target price on shares of Tempus AI in a report on Monday, June 1st. TD Cowen lifted their target price on Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a report on Monday, June 1st. Jefferies Financial Group initiated coverage on Tempus AI in a report on Monday, April 13th. They issued an “underperform” rating and a $35.00 target price for the company. Finally, Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday. Nine analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $68.64.

Insider Activity

In other news, CAO Ryan M. Bartolucci sold 4,116 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $181,392.12. Following the completion of the sale, the chief accounting officer directly owned 74,041 shares of the company’s stock, valued at approximately $3,262,986.87. The trade was a 5.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $46.70, for a total transaction of $7,763,875.00. Following the sale, the chief executive officer directly owned 8,808,533 shares of the company’s stock, valued at $411,358,491.10. This represents a 1.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 558,557 shares of company stock worth $26,611,939 in the last three months. Corporate insiders own 24.26% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.